Fallopian Tube Neoplasms
31 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Neoplasms
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| [11C]AZ1419 3391 + Palacaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| [11C]AZ1419 3391 + Palacaparib + Temozolomide for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for fallopian tube neoplasms | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bevacizumab + nivolumab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bevacizumab + nivolumab + rucaparib for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ceralasertib + Olaparib for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IMNN-001 for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Losartan + Paclitaxel for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine + Carboplatin for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mirvetuximab Soravtansine for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Olaparib for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Palacaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Palacaparib + Datopotamab Deruxtecan for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Palacaparib + Temozolomide for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pegylated liposomal doxorubicin + TOPOTECAN + Paclitaxel for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pembrolizumab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Questionnaire Administration + Dordaviprone + Paclitaxel for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant + nab-paclitaxel for fallopian tube neoplasms | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TRASTUZUMAB DERUXTECAN + Palacaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tremelimumab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TREMELIMUMAB + Olaparib for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tretinoin for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBAMATAMAB + Ubletamig + SARILUMAB for fallopian tube neoplasms | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Upifitimab rilsodotin for fallopian tube neoplasms | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Utidelone capsule 35mg/m2/d BID for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Utidelone capsule 40mg/m2/d BID for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Utidelone capsule 50mg/m2/d BID for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Utidelone capsule 75mg/m2/d QD for fallopian tube neoplasms | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vudalimab for fallopian tube neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.